Article Text

Download PDFPDF

Systematic review
Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia
  1. Paul Leeson
  1. Division of Cardiovascular Medicine, University of Oxford, Oxford, UK
  1. Correspondence to : Professor Paul Leeson, Oxford Cardiovascular Clinical Research Facility, John Radcliffe Hospital, Oxford OX3 9DU, UK; paul.leeson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Aspirin is recommended in current international guidelines for women at heightened risk for preeclampsia. Preeclampsia occurs in 2–8% of pregnancies and is a leading cause for both maternal and fetal morbidity and mortality. Effective prevention approaches therefore have the potential for significant health benefits. In 1996 the US Preventive Services Task Force produced a report on the identification, prevention and treatment of preeclampsia, stating:There is insufficient evidence to recommend for or against routine aspirin prophylaxis in pregnancy for the prevention of either preeclampsia […] or intrauterine growth retardation […]. Clinicians may wish to inform patients at high risk of preeclampsia that aspirin prophylaxis has been shown to …

View Full Text